FDA Brief

Warning letters Drugs

FDA warning letter to

Gascó Industrial Corporation

High riskIssued Feb 17, 2023Posted Feb 28, 2023Division of Pharmaceutical Quality Operations II

FDA cites Gascó Industrial for CGMP violations in OTC hand soap, antiseptics, and hand sanitizer, including shared equipment with industrial products.

What happened

FDA inspected the Gurabo, Puerto Rico drug manufacturing facility from October 11 to October 18, 2022. It found drugs made on the same equipment as industrial detergents and disinfectants, inadequate cleaning and water-system controls, no process validation, and quality-unit oversight failures. FDA reviewed the company’s November 15, 2022 response and called it inadequate.

What FDA found

  1. The firm used the same equipment to make drugs and non-pharmaceutical industrial detergents and disinfectants without adequate separate areas to prevent contamination or mix-up.

    21 CFR 211.42(c)
  2. The firm lacked adequate written production and process controls, including sufficient cleaning procedures, a validated water system, and process validation.

    21 CFR 211.100(a)
  3. The quality unit failed to ensure adequate testing of incoming components and finished drugs, thorough investigations, employee training, a stability program, and written procedures.

    21 CFR 211.22; 21 CFR 211.84(d); 211.165; 211.192; 211.25(a); 211.137(a); 211.22(d)

What FDA wants

FDA tells the company to correct the violations and respond in writing within 15 working days, including whether it will stop shared equipment use or provide a separation plan, risk assessments, cleaning and water-system remediation, process validation, and quality-unit fixes.

Who should pay attention

  • brands or distributors that buy OTC antiseptics or hand sanitizer from this manufacturer
  • contract manufacturers that share equipment between drug and industrial products
  • quality teams responsible for cleaning validation and water systems

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk